291289-50-4

Basic information

• Product Name: 4-(2,4-Difluoro-phenyl)-piperidine
• Synonyms: 4-(2,4-Difluorophenyl)piperidine;Piperidine, 4-(2,4-difluorophenyl)-;4-difluorophenyl)piperidine
• CAS NO: 291289-50-4
• Molecular Formula: C₁₁H₁₃F₂N
• Molecular Weight: 197.22
• Mol File: 291289-50-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 235.847 °C at 760 mmHg
• Flash Point: 96.437 °C
• Appearance: /
• Density: 1.126 g/cm³
• Vapor Pressure: 0.049mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: 2-8°C
• PKA: 10.03±0.10(Predicted)
• CAS DataBase Reference: 4-(2,4-Difluoro-phenyl)-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,4-Difluoro-phenyl)-piperidine(291289-50-4)
• EPA Substance Registry System: 4-(2,4-Difluoro-phenyl)-piperidine(291289-50-4)

Safety Data

• Hazardous Substances Data: 291289-50-4(Hazardous Substances Data)

Usage

General Description

4-(2,4-Difluoro-phenyl)-piperidine is a chemical compound that contains a piperidine ring and a difluorophenyl group. This organic compound is commonly used in pharmaceutical research and development as a building block for the synthesis of various drugs and biologically active molecules. Its structure and properties make it a valuable intermediate in the preparation of potential drug candidates, including those with potential applications in the treatment of neurological disorders, inflammation, and cancer. Additionally, the difluorophenyl group in the compound can impart specific pharmacological properties to the molecules it is incorporated into, making it an important component in drug discovery and design. As a result, 4-(2,4-Difluoro-phenyl)-piperidine is a key compound in the field of medicinal chemistry and drug development.

InChI:InChI=1/C11H13F2N/c12-9-1-2-10(11(13)7-9)8-3-5-14-6-4-8/h1-2,7-8,14H,3-6H2

Upstream product

• 863111-00-6 4-(2,4-difluorophenyl)-1,2,3,6-tetrahydropyridine 

Downstream Products

• 1065584-79-3 7-(2-(4-(2,4-difluorophenyl)piperidin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine 
• 1323404-17-6 3-(4-((3-((4-(2,4-DIFLUOROPHENYL)PIPERIDIN-1-YL)METHYL) BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE 
• 1254979-37-7 3-(cyclopropylmethyl)-7-[4-(2,4-difluorophenyl)-1-piperidinyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1254979-76-4 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-(2,4-difluorophenyl)-1-piperidinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine 

Relevant articles and documents

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators

The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.